Allergen Or Component Thereof (e.g., Ragweed Pollen, Etc.) Patents (Class 424/275.1)
  • Patent number: 11027010
    Abstract: The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: June 8, 2021
    Assignee: STALLERGENES
    Inventors: Philippe Moingeon, Thierry Batard, Bertrand Villet
  • Patent number: 10874736
    Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: December 29, 2020
    Assignee: ALK-ABELLO A/S
    Inventors: Heather Michelle Webster, Jason Daniel Frey, Trena Larissa Repp, Craig T. Grass, David Rowles, Gary Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vázquez, Juan Carlos Moreno Segura, Maria José Chamorro Salillas
  • Patent number: 10792359
    Abstract: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glycopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from lot to lot without the fluctuations in contaminants or activity that compromise natural-product adjuvants. Also provided are vaccines and pharmaceutical compositions that include GLA and one or more of an antigen, a Toll-like receptor (TLR) agonist, a co-adjuvant and a carrier such as a pharmaceutical carrier.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: October 6, 2020
    Assignee: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Darrick Carter
  • Patent number: 10751286
    Abstract: The present invention includes compositions, methods of making and using the compositions for modulating the immune response in a subject by providing a vaccine composition having a pollen or spore disposed in a pharmaceutical carrier for delivery to a subject, wherein the pollen or spore comprises multiple pores that connect an outer surface of the pollen/spore to an inner cavity and one or more antigens disposed on the outer surface, in the inner cavity, in the multiple pores, or a combination thereof, wherein the one or more antigens modulate an immune responses in the subject.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: August 25, 2020
    Assignee: Texas Tech University System
    Inventors: Harvinder S. Gill, Shashwati Atwe, Yunzhe Ma
  • Patent number: 10512686
    Abstract: The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 24, 2019
    Assignee: Aimmune Therapeutics, Inc.
    Inventors: Bryan Walser, Howard V. Raff
  • Patent number: 10466250
    Abstract: Methods for determining an in vitro release profile of peanut allergens in a sample are provided. Methods for determining one or more signatures of peanut allergens in a sample are provided.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: November 5, 2019
    Assignee: SANOFI
    Inventors: Kim Alving, Pierre deMontigny, Bing Huang Wang
  • Patent number: 10342757
    Abstract: A cytomimetic formulation is provided comprising at least two of: (a) a fermented truffle extract; (b) a plurality of hyaluronic acids of different molecular weight, ranging from 50 KDa up to 2000 KDa; (c) an olive leaf extract in a mineral-containing water; and (d) a fermented grape must. The formulations mimic the skin cytoplasmic environment and create optimal conditions for cellular growth and skin rejuvenation. Methods of use and processes for manufacturing thereof are also provided.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: July 9, 2019
    Assignee: Mitani Group, Inc.
    Inventors: Mirela Mitan, Mario De Rosa, Mosè Rossi
  • Patent number: 10195276
    Abstract: A method for the production of hydrolyzed allergens from allergens comprising the steps of: a) extracting a source of allergens comprising allergenic proteins to form an extract, b) purifying the extract to remove non-protein components to form a purified extract, c) denaturing the purified extract with a first denaturing agent to form a purified denatured extract, d) refining the purified denatured extract to remove impurities to form a refined denatured extract, e) denaturing the refined denatured extract with a second denaturing agent to form denatured allergen mixture, and f) hydrolyzing the denatured allergen mixture to form the hydrolyzed allergens.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: February 5, 2019
    Assignee: BIOTECH TOOLS S.A.
    Inventors: Gael Placier, Laetitia Frisch, Thierry Legon, Marie-Ange Benoit
  • Patent number: 10022440
    Abstract: The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: July 17, 2018
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
    Inventors: Clive Henry Wasserfall, Mark A. Atkinson, Benjamin George Keselowsky, Young Mee Yoon
  • Patent number: 9795644
    Abstract: The invention relates to grass pollen extracts containing reduced amount of flavonoid glycosides in order to minimize the risks of genotoxicity of the grass pollen extracts. The invention also relates to a method of preparing grass pollen extracts containing reduced amount of flavonoid glycosides by ultrafiltration. Flavonoid glycosides are naturally present in grass pollen extracts and they have been identified as being responsible for the formation of flavonoid aglycones, which are genotoxic in vitro, under the influence of enzymes contained in the grass pollen extracts.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: October 24, 2017
    Assignee: STALLERGENES
    Inventors: Philippe Moingeon, Thierry Batard, Bertrand Villet
  • Patent number: 9724271
    Abstract: Infant pacifiers, compositions, and methods of use thereof, for preventing or reducing risk of developing a hyperallergenic immune system or allergic condition are provided.
    Type: Grant
    Filed: May 2, 2011
    Date of Patent: August 8, 2017
    Assignee: Allovate, LLC
    Inventor: Cedric Francois
  • Patent number: 9526781
    Abstract: The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals, such as human mammals, suffering from peanut allergy. The present invention further relates to the use of the present compositions for the therapeutic treatment for desentizing the immune system of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment of a mammal with high predisposition to develop a certain allergy. Specifically, the present invention relates to pharmaceutical compositions comprising a modified whole peanut extract and pharmaceutically acceptable diluents and/or excipients, wherein said modified whole peanut extract is a reduced and subsequently alkylated whole peanut extract, preferably a whole defatted peanut extract comprising soluble peanut kernel proteins such as Ara h1, Ara h2 and Ara h6.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: December 27, 2016
    Assignee: HAL Allergy Holding B.V.
    Inventors: Stefan Johan Koppelman, Joanna Paulina Maria van der Kleij
  • Patent number: 9522939
    Abstract: The present invention relates to recombinant DNA molecules which encode chimeric polypeptides of differing allergens of Parietaria judaica which can be used for the prevention and treatment of allergies, in particular pollen allergies. Specifically, chimeric polypeptides composed of fragments of the allergens Par j 1 and Par j 2 having hypoallergenic characteristics are described. Methods for producing these recombinant polypeptides in heterologous expression systems are also described. Efficient methods of purifying the chimeric proteins are also described.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: December 20, 2016
    Assignee: Bial Industrial Farmaceutica, S.A.
    Inventors: Juan Andres Asturias, Alberto Martinez Garate, Roberto Gonzales Rioja
  • Patent number: 9481716
    Abstract: The present invention relates to oral immunotherapy for the desensitization of patients who are hypersensitive to peanut allergen. The immunotherapy comprises increasing the oral dose daily dose of peanut protein administered to the patient at intervals of at least 2 weeks in a series of increments from an initial dose to a maximum dose, the series of dose increments including 2 mg, 5 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg and 800 mg; administering a daily oral dose of the maximum dose of peanut protein for at least 2 years and then administering a weekly oral dose of the maximum dose of peanut protein for at least 2 years.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: November 1, 2016
    Assignee: Cambridge Univeristy Hospitals NHS Foundation Trust
    Inventors: Andrew Clark, Pamela Ewan
  • Patent number: 9408805
    Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.
    Type: Grant
    Filed: May 27, 2014
    Date of Patent: August 9, 2016
    Assignees: ALK-Abello A/S, R.P. Scherer Technologies, LLC
    Inventors: Henrik Hugo Jacobi, Annette Roemmelmayer Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
  • Patent number: 9259464
    Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: February 16, 2016
    Assignee: ALK-Abelló A/S
    Inventors: Heather M. Webster, Jason Daniel Frey, Trena L. Repp, Craig T. Grass, David Rowles, Gary Smith, Domingo Barber Hernandez, Fernando Juan Vidales, Carmen Arteaga Vazquez, Juan Carlos Moreno Segura, Maria Jose Chamorro Salillas
  • Publication number: 20150147283
    Abstract: The present invention provides methods for limiting development of skin wounds, and also for treatment of one or more of erythemas, blisters, rashes, pruritis, contact dermatitis, psoriasis, eczema, acne, and athlete's foot.
    Type: Application
    Filed: March 14, 2013
    Publication date: May 28, 2015
    Inventors: Kathleen E. Rodgers, Gere S. diZerega
  • Patent number: 9040054
    Abstract: The present invention relates to a hypoallergenic molecule consisting of Bet v Ia or an allergen having at least 40% identity to Bet v Ia comprising mutations of at least four amino acid residues in the region of amino acids 100 to 125 of Bet v Ia or its corresponding region of the allergen having at least 40% identity to Bet v 1a.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: May 26, 2015
    Assignee: BIOMAY AG
    Inventors: Michael Wallner, Barbara Bohle, Martin Himly, Nicole Wopfner, Gabriele Gadermaier, Matthias Egger, Peter Lackner, Fatima Ferreira, Michael Hauser
  • Publication number: 20150140040
    Abstract: Provided herein are methods of populating a target tissue of interest of a subject with particles of a substance of interest by precipitation. Example methods include administering a solution to a subject, the solution including the substance of interest and a pharmaceutically acceptable solvent. The substance of interest must be soluble in a pharmaceutically acceptable, water-miscible solvent but insoluble in tissue fluids of the target tissue of interest; and the pharmaceutically acceptable solvent must be freely miscible with the tissue fluids of the target tissue of interest. According to example embodiments, the solution is administered in a volume of the pharmaceutically acceptable solvent that will be diluted by tissue fluids in the target tissue of interest following administration at a rate that will result in precipitation of an effective amount of particles of the substance of interest in a range of sizes that will accomplish a purpose for which the substance is administered.
    Type: Application
    Filed: December 11, 2014
    Publication date: May 21, 2015
    Inventors: Robert E. COIFMAN, Catherine F. YANG
  • Publication number: 20150125495
    Abstract: The present invention provides a thin mucoadhesive sublingual film composition which provides improved allergen delivery and efficacy at a smaller dose while prolonging the contact time between the allergen and oral antigen presenting cells (APCs), and therefore minimizing the risk of systemic side effects. The thin film compositions of the present invention are also easier to standardize, and removes any need for measuring allergen doses at the physician's office, and which allows for a simplified dosing schedule. Methods of making the thin film compositions and methods for their use are also disclosed.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 7, 2015
    Applicant: John Hopkins University
    Inventors: Robert Wood, Hai-Quan Mao, Corinne Keet, Russell Martin
  • Publication number: 20150118264
    Abstract: The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.
    Type: Application
    Filed: January 31, 2013
    Publication date: April 30, 2015
    Applicant: CureVac GMBH
    Inventors: Patrick Baumhof, Thomas Kramps, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek
  • Publication number: 20150118183
    Abstract: The present invention is directed to a pharmaceutical composition including (e.g., for use as an adjuvant) a (negatively charged) nucleic acid comprising complex comprising as a carrier cationic or polycationic compounds (e.g. peptides, proteins or polymers) and as a cargo at least one nucleic acid (molecule) and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.
    Type: Application
    Filed: January 31, 2013
    Publication date: April 30, 2015
    Applicant: CUREVAC GMBH
    Inventor: Patrick Baumhof
  • Publication number: 20150110819
    Abstract: The invention provides Cockroach proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses and medicaments of such proteins, peptides, subsequences, portions, homologues, variants and derivatives thereof. Such methods, uses and medicaments include modulating an immune response, protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease and inducing immunological tolerance to the allergen (e.g., Cockroach allergen) in a subject.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 23, 2015
    Inventors: Alessandro Sette, Bjoern Peters, Jason Greenbaum
  • Patent number: 9005627
    Abstract: Contiguous overlapping peptides (COPs) for the treatment of allergic patients by Specific Immunotherapy (SIT) are provided from the sequence of the major allergen of ragweed pollen Amb a 1. Such peptides while providing all potential T cell epitopes are devoid of the three-dimensional structure of the original allergen, therefore reducing their ability to bind IgE.
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: April 14, 2015
    Assignee: Anergis S.A.
    Inventors: Christophe Reymond, Francois Spertini
  • Publication number: 20150098969
    Abstract: Pharmaceutical formulations, which may be used for preventing or treating allergy to moulds of the Alternaria and/or Cladosporium genus, comprising a pharmaceutically acceptable carrier or diluent and a polypeptide or a pharmaceutically acceptable salt thereof selected from at least three of: (a) a polypeptide comprising the amino acid sequence of WSWKIGPAIATGNT (Alt28; SEQ ID NO: 101) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (b) a polypeptide comprising the amino acid sequence of KYRRVVRAGVKVAQTAR (Alt34A; SEQ ID NO: 107) or a T cell epi tope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (c) a polypeptide comprising the amino acid sequence of KYAGVFVSTGTLGGG (SEQ ID NO: 112) or a T cell epitope-containing variant sequence derived from said amino acid sequence, or a said salt thereof; (d) a polypeptide comprising the amino acid sequence of AEVYQKLKALAKKTYGQ (Alt13A; SEQ ID NO: 83) or a T cell epi
    Type: Application
    Filed: May 30, 2013
    Publication date: April 9, 2015
    Inventors: Roderick Peter Hafner, Paul Laidler, Pascal Hickey, Mark Larche
  • Patent number: 8999348
    Abstract: The present invention relates to the preparation and use of recombinant variants of group 6 allergens of the Poaceae (true grasses), which are characterized by reduced IgE reactivity compared with known wild-type allergens and at the same time substantially retained reactivity with T-lymphocytes.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: April 7, 2015
    Assignee: Merck Patent GmbH
    Inventors: Martin Wald, Andreas Nandy, Helmut Fiebig, Bernhard Weber, Helga Kahlert, Gerald Reese, Oliver Cromwell
  • Publication number: 20150086593
    Abstract: Compositions, methods, and kits for inhibiting an allergic response against an allergenic protein are disclosed. Compositions, methods and kits for inhibiting an allergic response against a flea allergenic protein; a feline allergenic protein; a canine allergenic protein; a dust mite allergenic protein; a peanut allergenic protein; a Japanese cedar allergenic protein; and a blomia tropicalis allergenic protein are disclosed.
    Type: Application
    Filed: June 27, 2014
    Publication date: March 26, 2015
    Inventors: Bin Wang, Huali Jin, Youmin Kang, Hsien-Jue Chu, Terry Kaleung Ng
  • Publication number: 20150086594
    Abstract: The present disclosure relates to a method for the treatment of allergic conditions. In said method the allergens to which an individual is susceptible is identified as per the allergy profile and accordingly a formulation having potentized dispersions of each of the identified allergens is administered to the individual for a predetermined period and at a predetermined potency. The present disclosure also relates to a formulation which is a mixture of potentized dispersions of each of the identified allergens and the method of preparation for the same. The present disclosure further relates to a kit consisting of at least one allergen, at least one vehicle and accessories which include bottles and mixing sticks.
    Type: Application
    Filed: May 2, 2013
    Publication date: March 26, 2015
    Inventor: Mohan DEWAN
  • Publication number: 20150071960
    Abstract: Glycosphingolipids (GSLs) bearing ?-glucose (?-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with ?-glucose (?-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with ?-galactose (?-Gal) are disclosed. GSLs bearing ?-glucose (?-Glc) and derivatives of ?-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with ?-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with ?-Glc and derivatives thereof are provided.
    Type: Application
    Filed: September 8, 2014
    Publication date: March 12, 2015
    Inventors: Chi-Huey WONG, Alice L. Yu, Kun-Hsien Lin, Tai-Na Chen
  • Publication number: 20150071967
    Abstract: The present invention relates to a composition comprising a tolerogenic peptide and a GSK-3 inhibitor and uses thereof. The invention also relates to the use of a GSK-3 inhibitor to accelerate the peptide-mediated shift in secretion profile of lymphocytes from pro-inflammatory to anti-inflammatory cytokines. The GSK-3 inhibitor may be used to enhance antigen-specific immunotherapy.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 12, 2015
    Inventors: David Wraith, Elaine Hill
  • Publication number: 20150072007
    Abstract: The present invention relates to a non-invasive medical therapy and a composition for avoiding organ transplantation, or controlling biological rejection of transplanted organs, or treating organs under consideration for replacement by transplant, and otherwise treating aged, diseased and/or abnormal tissues and/or organs. More specifically, the non-invasive medical therapy involves administering to a patient an elemental nutritional feeding comprising a free amino acid profile simulating and/or replicating a targeted diseased or transplanted tissue and/or organ. The subject invention provides methods of inactivating reactive component epitopes of moieties pathogenic substances or producing immunogenic compositions containing pathogenic substances comprising contacting pathogenic substances, or compositions containing pathogenic substances, with super critical carbon dioxide or liquid nitrogen. Similar benefits are produced using high HLB surfactants also reducing carcinogenic factors.
    Type: Application
    Filed: September 11, 2014
    Publication date: March 12, 2015
    Inventor: LEONARD S. GIRSH
  • Publication number: 20150056229
    Abstract: The present invention relates to the provision of a DNA sequence of the major grass pollen allergen Lol p 4. The invention also encompasses fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for in vitro and in vivo diagnosis of pollen allergies.
    Type: Application
    Filed: November 7, 2014
    Publication date: February 26, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Andreas NANDY, Helmut FIEBIG, Oliver CROMWELL
  • Publication number: 20150056149
    Abstract: A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.
    Type: Application
    Filed: August 27, 2014
    Publication date: February 26, 2015
    Inventors: Dov Tamarkin, Elana Gazal, Irakliy Papiashvili, Yohan Hazot, David Schuz, Rita Keynan
  • Patent number: 8951530
    Abstract: The present invention refers to recombinant ADN molecules coding to hybrids polypeptides of different allergens from D. pteronyssinus useful for the prevention and treatment of allergies, particularly allergies caused by mites. Specifically, the invention describes hybrid proteins composed of fragments of allergens Derp p 1 y Derp p 2 with hypoallergenic characteristics and maintain their immunogenic capacity, being particularly useful for the treatment of allergy. The invention also describes the production methods of these polypeptides in heterologous expression systems. Besides, the invention describes efficient purification methods of these hybrid proteins.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: February 10, 2015
    Assignee: Bial Industrial Farmaceutica, S.A.
    Inventors: Juan Andrés Asturias Ortega, Iñaki Ibarrola Lopez De Davalillo, Maria Carmen Arilla Rodriguez, Alberto Martinez Garate
  • Patent number: 8945574
    Abstract: The invention provides hypoallergenic variants of Bet v 1 major allergen from Betula verrucosa plant pollen and the use thereof for the preventive or therapeutic treatment of allergic diseases.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: February 3, 2015
    Assignee: Lofarma S.p.A.
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo, Paolo Falagiani
  • Publication number: 20150024007
    Abstract: The invention provides methods for treating asthma by using multiple rounds of administration of ISS over a period of time to confer long term disease modification.
    Type: Application
    Filed: July 18, 2014
    Publication date: January 22, 2015
    Inventors: Edith M. HESSEL, Robert L. Coffman
  • Patent number: 8932596
    Abstract: The present invention relates to the treatment of EE. More specifically, the invention relates to a new method of treating EE through the epicutaneous route. In particular, the method of the invention comprises applying to the skin of the subject a skin patch device, comprising a composition, under conditions allowing a contact between said composition and the skin. The present invention also relates to the skin patch device and to a use of the skin patch device in the manufacture of a composition for treating eosinophilic esophagitis in a subject.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: January 13, 2015
    Assignee: DBV Technologies
    Inventors: Pierre-Henri Benhamou, Lucie Mondoulet
  • Publication number: 20140377311
    Abstract: The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.
    Type: Application
    Filed: February 4, 2013
    Publication date: December 25, 2014
    Applicant: DBV TECHNOLOGIES
    Inventors: Pierre-Henri Benhamou, Christophe Dupont, Lucie Mondoulet
  • Publication number: 20140377310
    Abstract: Disclosed are methods to treat allergic conditions, including pulmonary and non-pulmonary conditions, in a subject by administering a composition that inhibits Pim kinase. Also disclosed are methods to treat allergic conditions in a subject by administering a composition that induces expression of Runx3.
    Type: Application
    Filed: June 30, 2014
    Publication date: December 25, 2014
    Inventors: Erwin W. Gelfand, Meiqin Wang
  • Publication number: 20140370086
    Abstract: Sublingual immunotherapy (SLIT) with reduced oral itchiness is disclosed. The improved sublingual immunotherapy combines a monotonically increasing dose of allergen, along with a constant dose of mast cell stabilizer, thereby substantially avoiding the oral itchiness and other uncomfortable adverse reactions typically experienced with SLIT, which can improve patient compliance. An antihistamine and/or a leukotriene inhibitor can also be added along with the mast cell stabilizer. Multi-layer and/or coated tablets, and flexible paired ampoules with special features to advantageously time the dose of the allergen relative to the dose of the mast cell stabilizer, have been provided to effectively administer the improved sublingual immunotherapy in a highly convenient manner.
    Type: Application
    Filed: June 17, 2013
    Publication date: December 18, 2014
    Inventors: Ziv Harish, Russ Weinzimmer
  • Publication number: 20140363470
    Abstract: The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals, such as human mammals, suffering from peanut allergy. The present invention further relates to the use of the present compositions for the therapeutic treatment for desentizing the immune system of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment of a mammal with high predisposition to develop a certain allergy. Specifically, the present invention relates to pharmaceutical compositions comprising a modified whole peanut extract and pharmaceutically acceptable diluents and/or excipients, wherein said modified whole peanut extract is a reduced and subsequently alkylated whole peanut extract, preferably a whole defatted peanut extract comprising soluble peanut kernel proteins such as Ara h1, Ara h2 and Ara h6.
    Type: Application
    Filed: December 14, 2012
    Publication date: December 11, 2014
    Inventors: Stefan Johan Koppelman, Joanna Paulina Maria Van Der Kleij
  • Publication number: 20140328881
    Abstract: Disclosed are hypoallergenic variants of PhI p 5, the major allergen from Phleum pratense, and the uses thereof in the treatment of allergic diseases.
    Type: Application
    Filed: December 18, 2012
    Publication date: November 6, 2014
    Inventors: Giovanni Mistrello, Stefania Zanotta, Daniela Roncarolo
  • Publication number: 20140314865
    Abstract: The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comprising at last one targeting moiety and optionally at least one immunostimulatory agent. The invention provides pharmaceutical compositions comprising inventive vaccine nanocarriers. The present invention provides methods of designing, manufacturing, and using inventive vaccine nanocarriers and pharmaceutical compositions thereof. The invention provides methods of prophylaxis and/or treatment of diseases, disorders, and conditions comprising administering at least one inventive vaccine nanocarrier to a subject in need thereof.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 23, 2014
    Applicants: Massachusetts Institute of Technology, Immune Disease Institute, President and Fellows of Harvard College, Partners Healthcare System, Inc.
    Inventors: Massachusetts Institute of Technology, Partners Healthcare System, Inc., President and Fellows of Harvard College, Immune Disease Institute
  • Publication number: 20140314739
    Abstract: The present invention provides a composition comprising or consisting of inulin particles for use in the reduction or inhibition of inflammation, and/or for treating or preventing inflammatory disease, in a subject. Also provided is a pharmaceutically acceptable composition comprising: particles of inulin; and a substance comprising or consisting of one or more pathogen-associated molecular patterns (PAMPs), or an equivalent kit of parts, and methods and uses of the composition and kit for inducing or modulating an immune response in a subject, such as modulating an immune response to an antigen or allergen and/or as a vaccine. Also provided is a single-dose vaccine composition comprising inulin particles, an antigen and, optionally, an antigen-binding carrier material, and methods and uses of the vaccine.
    Type: Application
    Filed: June 19, 2012
    Publication date: October 23, 2014
    Applicant: Vaxine Pty Ltd.
    Inventor: Nikolai Petrovsky
  • Publication number: 20140301953
    Abstract: The invention relates to test kits for the determination of allergic dermatitis caused by insect bites in an animal such as horses, and to compositions and methods for desensitization. It was found that a culture supernatant or a cell extract of Sf21 insect cells is suitable for reliable test kits and for compositions for desensitization.
    Type: Application
    Filed: October 5, 2012
    Publication date: October 9, 2014
    Inventors: Beat Bigler, Andrew Hemphill, Joachim Muller
  • Publication number: 20140302153
    Abstract: Methods of the prophylaxis of the development of allergy in a patient at risk of sensitization to an antigen(s) or allergen(s) due to impaired gastrointestinal functions include administering a mast cell inhibitor, e.g., ketotifen, e.g., ketotifen fumarate. Methods for prophylactically treating, reducing, delaying or controlling gastrointestinal disorders include administering a mast cell stabilizer, e.g., ketotifen to a patient in need thereof. Pharmaceutical preparation, composition for use in methods described, are also disclosed. Also disclosed are methods of prophylaxis or treating gastrointestinal and esophageal inflammation, and methods for the prophylaxis of the development of additional allergies to a newly introduced substance in a patient with a preexisting allergy. Such methods include delivery of a mast cell stabilizer, e.g., ketotifen. Oral and topical administration are contemplated within the scope of the methods.
    Type: Application
    Filed: April 7, 2014
    Publication date: October 9, 2014
    Applicant: MASTCELL PHARMACEUTICALS, INC.
    Inventor: Dennis PENN
  • Publication number: 20140271836
    Abstract: The present application relates to a method for managing the development and manufacturing process of a therapeutically effective formulation. Peanut proteins are characterized from peanut flour and encapsulated formulations made using the peanut flour for oral immunotherapy of peanut allergies.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Allergen Research Corporation
    Inventors: Bryan Walser, Howard V. Raff
  • Publication number: 20140271827
    Abstract: The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.
    Type: Application
    Filed: April 30, 2014
    Publication date: September 18, 2014
    Applicant: Massachusetts Institute of Technology
    Inventors: Darrell J. Irvine, Jaehyun Moon
  • Publication number: 20140271722
    Abstract: The invention provides allergen containing pharmaceutical products and in particular fast-dispersing solid allergen dosage forms. In particular, fast-dispersing, non-compressed solid dosage forms suitable for oromucosal administration comprising a matrix and at least one allergen are provided. Suitable matrices are gelatine, starch and mannitol. Methods for the dosage forms are also provided.
    Type: Application
    Filed: May 27, 2014
    Publication date: September 18, 2014
    Applicants: ALK-Abello A/S, R.P. Scherer Technologies, LLC
    Inventors: Henrik Hugo Jacobi, Annette Roemmelmayer Lundegaard, Christian Gauguin Houghton, Stig Aasmul-Olsen, Lise Lund Maerkedahl, Jan Sondergaard Andersen, Kerry Mallindine, Owen James Murray, Susan Gerrard Banbury, Desmond Yik Teng Wong, Lisa Marie Garrett, Michael Hall
  • Publication number: 20140271721
    Abstract: The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: Allergen Research Corporation
    Inventors: Bryan Walser, Howard V. Raff